ArticleJournal of bone oncology2026
Primary osseous chest wall sarcomas: Oncological and surgical outcomes in a large single-institution cohort of 100 patients.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Primary osseous chest wall sarcomas: Oncological and surgical outcomes in a large single-institution cohort of 100 patients".Journal of bone oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary osseous chest wall sarcomas are rare tumours with limited evidence guiding surgical management. This study aimed to evaluate oncological outcomes, complication rates, and prognostic factors associated with survival in a large, single-institution cohort. Methods: We retrospectively reviewed 100 patients who underwent chest wall resection for primary osseous sarcoma between 1994 and 2022. Outcomes included overall survival (OS), event-free survival (EFS), local recurrence (LR), distant metastasis (DM), and postoperative complications. The cumulative incidence of LR and DM were estimated using competing risk models. Prognostic factors were analysed with Cox regression. Results: The cohort included 79 patients with chondrosarcoma, eight with osteosarcoma, and 13 with Ewing sarcoma. Negative margins (R0) were achieved in 79%. Reconstruction was performed in 68%, most commonly with mesh. Postoperative complications occurred in 19%. Five-year OS was 79% (70-87%) for the entire cohort, and by subtype: osteosarcoma 38% (4-71%), Ewing sarcoma 67% (41-94%), and chondrosarcoma 85% (77-94%). Recurrence patterns differed, osteosarcoma showed a high 5-year risk of DM (75% (40-100%)), chondrosarcoma predominantly exhibited LR (15% (7-23%)), and Ewing sarcoma both LR (15% (0-36%)) and DM (40% (11-69%)). Notably, grade 1 chondrosarcoma showed metastatic potential, emphasizing that the risk of distant metastasis should also be considered in these low-grade tumours, with a 5-year cumulative incidence of distant metastasis was 11% (95% CI: 0-27%). Tumour size and residual tumour (R1/2) were associated with worse outcomes. Conclusions: Radical resection (R0) remains the most important predictor of survival. 5-year survival differs substantially by subtype (chondrosarcoma 85%, Ewing sarcoma 67% and osteosarcoma 38%), while tumour size is associated with a less favourable prognosis. Individualized reconstructive strategies enable complex resections with acceptable morbidity (19% postoperative complications).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.